The Wall Street Journal (8/3, Rockoff, Subscription Publication) reports that in a securities filing on Thursday, Johnson & Johnson revealed that it has reached an agreement in principle with the Justice Department and some states on the settlement of probes into marketing practices, including the promotion of the antipsychotic drug Risperdal.

The Newark (NJ) Star-Ledger (8/3) reports, “The tentative settlement would resolve claims brought by authorities in California and Massachusetts that the company's subsidiary, Janssen Pharmaceuticals, inappropriately marketed the schizophrenia drug Invega and Natrecor, a treatment for congestive heart failure. Johnson & Johnson is expected to pay as much as $2.2 billion to settle the government pro